Peppermint oil, regardless of whether it is released in the small intestine or in the ileocolon, is ineffective for overall symptom relief in irritable bowel syndrome (IBS), a new study has found. In contrast, it shows significant efficacy for abdominal pain, discomfort and disease severity.
Unusual involvement of the eyes with atypical presentations may occur in patients with inflammatory bowel diseases (IBD) on antitumour necrosis factor (anti-TNF) therapy, according to a recent study presented at the 2019 Advances in Inflammatory Bowel Diseases Annual Meeting (AIBD 2019).
The choice of stress ulcer prophylaxis strategy – proton pump inhibitor (PPI) or histamine-2 receptor blocker (H2RB) – did not affect mortality within 90 days of admission to the intensive care unit (ICU), according to results of the PEPTIC* trial presented at the recent Critical Care Reviews Meeting (CCR20).
Use of adalimumab or infliximab in biologic-naïve patients with inflammatory bowel disease (IBD) delivers comparable rates of corticosteroid-free remission, as shown by a study presented at the Advances in Inflammatory Bowel Disease (AIBD) Conference 2019.
In patients with ulcerative colitis (UC), changes in histologic and endoscopic scores appear to be weakly to moderately predictive of each other, according to an analysis of the HICKORY study presented at the 2019 Advances in Inflammatory Bowel Diseases Annual Meeting (AIBD 2019).
Most patients with moderately to severely active ulcerative colitis and Crohn’s disease on vedolizumab persist with their treatment for up to 5 years, according to a posthoc analysis of the phase III GEMINI long-term safety (LTS) study presented at the Advances in Inflammatory Bowel Diseases (AIBD) 2019 Annual Meeting.
Individuals with new-onset prediabetes/diabetes after non-necrotizing acute pancreatitis (NODAP) more often have reduced insulin sensitivity, β-cell compensation, and no significant change in postprandial levels of glucagon and pancreatic polypeptide, suggests a study.
The use of oral liposomal iron in the treatment of mild anaemia in inflammatory bowel disease (IBD) patients appears to be effective, producing improvements in haemoglobin levels and quality of life with parallel reductions in fatigue, according to a study presented at the Advances in Inflammatory Bowel Diseases (AIBD) 2019 Annual Meeting.